Search Results 311-320 of 16674 for alopecia

1. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

   excluding alopecia. - Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within 28 days of starting the study drug ...

2. SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients - Mayo Clinic

   The presence of alopecia or peripheral neuropathy ≤ Grade 2 without pain is allowed. Previous allogeneic stem cell transplantation with active Graft Versus ...

3. Antiphospholipid syndrome - Symptoms & causes - Mayo Clinic

   Learn about causes and treatment of this blood disorder that mainly affects women and may cause blood clots and miscarriages.

4. A Study to Evaluate AZD1775 in Women with Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma - Mayo Clinic

   investigator. 2. With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events ...

5. A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

6. Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer - Mayo Clinic

   Recovered from prior chemotherapy (i.e., toxicities ≤ grade 1 [except for neuropathy and alopecia]); Thoracic radiotherapy administered concurrently with or ...

7. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

   *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...

8. Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. An untreated tumor growth ...

9. Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer - Mayo Clinic

   Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not ...

10. A Study to Evaluate TAB006, as Monotherapy and in Combination with Toripalimab, in Patients with Previously Treated, Advanced Malignancies - Mayo Clinic

    ... alopecia or autoimmune endocrinopathy that is clinically stable on hormone ... History of active autoimmune disease within the past 2 years, with the following ...